Why Shouldn't I Drink Grapefruit Juice With My...
Any number of medications can apply to this question: Prozac, BuSpar, Tegretol, Verapamil, Prednisone and a host of others - even Viagra! There are a large number of other medications affected by grapefruit juice as well, including all the cholesterol-lowering statins and even some antibiotics and birth control pills. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - July 21, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news
Immunosuppression With Prednisone for Restenosis PreventionImmunosuppression With Prednisone for Restenosis Prevention
What are the clinical benefits of oral prednisone when compared with bare metal stents -- for restenosis prevention? European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Rayos (Prednisone Delayed-Release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2013 Category: Drugs & Pharmacology Source Type: news
EPOCH-Rituximab Therapy Obviates Need for Radiotherapy in B-Cell Lymphoma
A dose-adjusted regimen of etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) obviated the need for radiotherapy in patients with primary mediastinal B-cell lymphoma in a single-group, phase II, prospective study. (Source: Cancer Network)
Source: Cancer Network - April 23, 2013 Category: Cancer & Oncology Source Type: news
Abiraterone and Prednisone Improve Prostate Cancer SurvivalAbiraterone and Prednisone Improve Prostate Cancer Survival
The final numbers extend previous data beyond the interim analysis. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 5, 2013 Category: Consumer Health News Tags: Urology News Source Type: news
RCT: Bendamustine plus rituximab vs CHOP plus rituximab as first-line treatment for indolent and mantle-cell lymphomas
Source: Lancet
Area: News
Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is considered the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma, however there are no randomised comparative study data to show that this regimen is better than other chemotherapy regimens. Bendamustine plus rituximab is effective for relapsed or refractory disease and based on long-standing experience of its use in Germany, this prospective, randomised, open-label non-inferiority study compared this regimen with ...
Source: NeLM - News - February 20, 2013 Category: Drugs & Pharmacology Source Type: news
Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)
Orlando, Fla., February 12, 2013 – Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA® (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2013 Category: Pharmaceuticals Source Type: news
Follow-up Data Show ZYTIGA? Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)
Orlando, Fla., February 12, 2013 ? Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA? (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer..... (Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2013 Category: Pharmaceuticals Source Type: news
Etanercept no better than prednisone for COPD exacerbations
Results from a randomized, double-blind, controlled trial suggest that the tumor necrosis factor α antagonist etanercept is no more effective than standard therapy with prednisone for the treatment of acute exacerbations in patients with chronic obstructive pulmonary disease. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - February 8, 2013 Category: Respiratory Medicine Source Type: news
TNF Alpha Antagonists for Acute Exacerbations of COPDTNF Alpha Antagonists for Acute Exacerbations of COPD
Does etanercept provide more effective anti-inflammatory treatment than prednisone -- for acute COPD exacerbations? Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 7, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
FDA Updates Lopinavir/Ritonavir (Kaletra) Labeling to Include New Drug Interaction Information
"On January 17, 2013, FDA approved revisions to the Kaletra (lopinavir/ritonavir) labels to include new drug interaction information. The following updates were included.
"Anticoagulants: Rivaroxaban. Avoid concomitant use of rivaroxaban and Kaletra. Coadministration of Kaletra and rivaroxaban is expected to result in increased exposure of rivaroxaban which may led to risk of increased bleeding
"Anticonvulsants: Lamotrigine and valproate. Coadministration of Kaletra and lamotrigine or valproate may decrease the exposure of lamotrigine or valproate. A dose increase of the lamotrigine or valproate may be nee...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 22, 2013 Category: Infectious Diseases Source Type: news
Crusted Scabies
A 40-year-old woman who had been receiving prednisone and azathioprine for the treatment of systemic lupus erythematosus complained of a widespread, intensely pruritic, heavily scaling skin rash. (Source: Consultant Live)
Source: Consultant Live - January 17, 2013 Category: Primary Care Source Type: news
AWMSG issues Final Appraisal Recommendation on bortezomib (Velcade®) subcutaneous injection
Source: All Wales Medicines Strategy Group (AWMSG)
Area: Evidence > Drug Specific Reviews
In its Final Appraisal Recommendation, the All Wales Medicines Strategy Group (AWMSG) is of the opinion that bortezomib (Velcade®) 3.5 mg subcutaneous injection is appropriate for specialist only prescribing within NHS Wales, as an alternative to the intravenous injection, for the following indications:
. treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.
. in com...
Source: NeLM - Drug Specific Reviews - January 17, 2013 Category: Drugs & Pharmacology Source Type: news
Abiraterone (Zytiga®) approved in the EU for treatment of metastatic castration-resistant prostate cancer prior to chemotherapy
Source: BioSpace
Area: News
According to BioSpace, the European Commission (EC) has approved an extension to the license of abiraterone to include its use, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. Abiraterone has until now has been approved only for use in men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
The approval follows a...
Source: NeLM - News - January 14, 2013 Category: Drugs & Pharmacology Source Type: news
Phase III study of 2-weekly versus 3-weekly docetaxel for castration-resistant advanced prostate cancer
Source: Lancet Oncology
Area: News
According to the results of a Phase III study published early online in The Lancet Oncology, a 2-weekly docetaxel regimen was well tolerated and improved time to treatment failure compared with the standard 3-weekly regimen in men with hormone-refractory prostate cancer.
The authors note that androgen deprivation is a standard treatment for advanced prostate cancer; it is not however curative and most patients develop castration-resistant disease within a median of 2 years. Several treatment options are available for patients with hormone-refractory prostate cancer, including...
Source: NeLM - News - January 7, 2013 Category: Drugs & Pharmacology Source Type: news
